Efficacy of long-term Skyrizi (risankizumab) treatment for moderate-to-severe plaque psoriasis over 256 weeks.

Quote:

---

Background:
Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate-to-severe plaque psoriasis.

Objectives:
To evaluate the long-term efficacy of risankizumab according to baseline patient characteristics, and for the treatment of high-impact disease manifestations (nail, scalp and palmoplantar psoriasis), through 256 weeks of continuous treatment in the phase 3 LIMMitless study.

Methods:
This subgroup analysis evaluated pooled data from patients with moderate-to-severe plaque psoriasis who were randomized to risankizumab 150 mg during two double-blind, phase 3, 52-week base studies (UltIMMa-1/2; NCT02684370/NCT02684357) and were enrolled in the phase 3 LIMMitless open-label extension study (NCT03047395). Subgroup assessments included the proportion of patients who achieved ≥90%/100% improvement in Psoriasis Area and Severity Index (PASI 90/100). Among patients with nail, scalp and/or palmoplantar psoriasis in addition to skin psoriasis, assessments included changes from baseline in and resolution of these three psoriatic manifestations.

Results:
Overall, a numerically similar proportion of patients (N = 525) achieved PASI 90/100 through Week 256, regardless of their baseline age, sex, body mass index, weight, PASI or psoriatic arthritis status. Patients with nail, scalp and/or palmoplantar psoriasis experienced substantial improvements in manifestation-specific indices (mean improvement from baseline to Week 256 of >81%, >94% and >97%, respectively); in patients with all three manifestations (N = 121), 44.6% achieved complete clearance of these manifestations at Week 256.

Conclusions:
Risankizumab demonstrated generally consistent efficacy through 256 weeks across patient subgroups and showed durable long-term efficacy for psoriatic disease manifestations.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Skyrizi (risankizumab)

(Sat-06-01-2024, 13:44 PM)Fred Wrote: Efficacy of long-term Skyrizi (risankizumab) treatment for moderate-to-severe plaque psoriasis over 256 weeks.

Quote:

---

Background:
Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate-to-severe plaque psoriasis.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Skyrizi (risankizumab)

Always when I see this intro’s, I get irritated..
The people who do this research are supposedly very well trained and highly educated.
They are working on a skin disease, they say over here. My feeling then says, that you will treat the skin….
But……. No… They are treating the immune system (Skyrizi is an IL-23 suppressor). So why are you treating the immune system, while you are talking about a skin disease… That is plain stupid.

Because if you treat the immune system, there must me something wrong in this immune system, right?
If there is something wrong with your eye, you treat the eye.
If there is something wrong with your leg, stretched or broken, then you treat the leg.
In both situations above, you might also give broader treatment to fight infection.
But in the case of psoriasis AND Psoriatic Arthritis, you only treat the immune system, as this really has the right effect.

So what they really are treating, is an Immune Mediated Inflamatory Disease that manifests on the skin AND  in (20-30-40%???) of the cases in the joints.

Stupid researchers.

In some ways I agree, but the immune system is causing an inflammatory skin disease that needs fixing. So both sayings are correct in my opinion.

(Sat-06-01-2024, 14:52 PM)Fred Wrote: In some ways I agree, but the immune system is causing an inflammatory skin disease that needs fixing. So both sayings are correct in my opinion.

To my idea it is not an inflammatory skin disease…. The skin is not sick, it is the fault of the immune system that causes the skin to inflame.

It relates a bit to this post [Group Specific], the derms have caught themselves in a dogma.

You also will agree that Psoriasis and Psoriatic Arthritis are quite the same disease. So they are also addressing only part of the disease.

Don't forget that the skin is an organ

Interesting as I just posted something to the effect of how psoriasis affects different organs. It started off like this:

Although many people think of psoriasis primarily as a skin disease, it is a systemic condition that affects other organs as well.

I mean it does affect the skin and some treatments are only for the skin and does nothing internal. But the disease is much more than just a "skin disease" so I get where you're coming from Caroline.

Thanks for the info Fred on Skyrizi!

(Sun-07-01-2024, 01:48 AM)Kat Wrote: Interesting as I just posted something to the effect of how psoriasis affects different organs. It started off like this:

Although many people think of psoriasis primarily as a skin disease, it is a systemic condition that affects other organs as well.

I mean it does affect the skin and some treatments are only for the skin and does nothing internal.  But the disease is much more than just a "skin disease" so I get where you're coming from Caroline. 

Thanks for the info Fred on Skyrizi! 

Well anyway, they can pat themselves on the back if they like but I don’t think it’s working that well on me..

Actually, what does ‘generally consistent efficacy’ really mean? I guess it’s not saying it’s great, just that it’s consistent?

(Sun-07-01-2024, 09:17 AM)Turnedlight Wrote: Actually, what does ‘generally consistent efficacy’ really mean? I guess it’s not saying it’s great, just that it’s consistent?

Yes, I think that is what they mean.
They do have acceptable results, probably varying from person to person, and that results are consistent.